Next Article in Journal
Impact of Hyper- and Hypo-Uricemia on Kidney Function
Next Article in Special Issue
Impact of Angiogenic and Cardiovascular Biomarkers for Prediction of Placental Dysfunction in the First Trimester of Pregnancy
Previous Article in Journal
Degradation and Failure Phenomena at the Dentin Bonding Interface
Previous Article in Special Issue
Tissue Factor Pathway Inhibitors as Potential Targets for Understanding the Pathophysiology of Preeclampsia
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Preeclampsia Susceptibility Assessment Based on Deep Learning Modeling and Single Nucleotide Polymorphism Analysis

by
Aida Saadaty
1,†,
Sara Parhoudeh
1,†,
Khalil Khashei Varnamkhasti
2,†,
Mehdi Moghanibashi
3 and
Sirous Naeimi
1,*
1
Department of Genetics, College of Science, Kazerun Branch, Islamic Azad University, Kazerun 73, Iran
2
Department of Medical Laboratory Sciences, Faculty of Medicine, Kazerun Branch, Islamic Azad University, Kazerun 73, Iran
3
Department of Genetics, Faculty of Medicine, Kazerun Branch, Islamic Azad University, Kazerun 73, Iran
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Biomedicines 2023, 11(5), 1257; https://doi.org/10.3390/biomedicines11051257
Submission received: 3 March 2023 / Revised: 3 April 2023 / Accepted: 21 April 2023 / Published: 24 April 2023
(This article belongs to the Special Issue The Pathophysiology of Preeclampsia)

Abstract

:
The early diagnosis of preeclampsia, a key outlook in improving pregnancy outcomes, still remains elusive. The present study aimed to examine the interleukin-13 and interleukin-4 pathway potential in the early detection of preeclampsia as well as the relationship between interleukin-13 rs2069740(T/A) and rs34255686(C/A) polymorphisms and preeclampsia risk to present a combined model. This study utilized raw data from the GSE149440 microarray dataset, and an expression matrix was constructed using the RMA method and affy package. The genes related to the interleukin-13 and interleukin-4 pathway were extracted from the GSEA, and their expression levels were applied to design multilayer perceptron and PPI graph convolutional neural network models. Moreover, genotyping for the rs2069740(T/A) and rs34255686(C/A) polymorphisms of the interleukin-13 gene were tested using the amplification refractory mutation system PCR method. The outcomes revealed that the expression levels of interleukin-4 and interleukin-13 pathway genes could significantly differentiate early preeclampsia from normal pregnancy. Moreover, the present study’s data suggested significant differences in the genotype distribution, the allelic frequencies and some of the risk markers of the study, in the position of rs34255686 and rs2069740 polymorphisms between the case and control groups. A combined test of two single nucleotide polymorphisms and an expression-based deep learning model could be designed for future preeclampsia diagnostic purposes.

1. Introduction

Pregnancy complications associated with new-onset elevated hypertension (systolic >140 mm Hg and diastolic >90 mm Hg on two occasions at least 4 h apart or shorter interval timing of systolic >160 mm Hg and diastolic >110 mm Hg) after 20 weeks’ gestation with accompanying proteinuria (≥300 mg upon 24 h urine collection; or UPCR ≥0.3 mg/mg; or urine protein dipstick reading ≥2+) is defined as preeclampsia. The frequency of other abnormal lab values such as thrombocytopenia, impaired liver function, epigastric pain, pulmonary edema or renal insufficiency can be categorized as severe preeclampsia [1,2]. This important pregnancy pathogenesis complicates 8–10% of all pregnancies and is a major cause of neonatal and maternal morbidity and mortality worldwide [3]. Moreover, this complication elevates the future risk of developing diabetes and cardiovascular disease for women suffering from preeclampsia and both short- and long-term consequences in their offspring [4]. The exact pathogenic molecular mechanisms of preeclampsia are still unclear and, except for delivery, no practical method for resolving preeclampsia symptoms is available [5]. Despite the fact that the etiology of preeclampsia has not yet been fully elucidated, the inflammatory response is known as a hallmark of preeclampsia, so pregnancy itself is a controlled inflammatory condition; however, preeclampsia can be classified as a pro-inflammatory state [6].
It is thought that cytokines as immunological modulators are involved in the development and progression of this pro-inflammatory situation. In normal pregnancy, T helper 2 cytokines (anti-inflammatory) such as interleukins (ILs) 4, 5 and 13 help to neutralize pro-inflammatory cytokines (T helper 1) such as interleukin 2 and gamma interferon. Several studies have noticed the imbalanced concentration of these pro- and anti-inflammatory cytokines in preeclampsia [7,8]. Genetic predisposition is thought to be responsible for the alteration of individual cytokine concentrations or their ratio for the pathophysiology of preeclampsia [9]. Several genetic studies have stated that various gene polymorphisms were associated with the risk of preeclampsia [10]. Cytokine genes’ single nucleotide polymorphisms (SNPs) may affect cytokine transcription and influence its expression level [11]. On the other hand, the role of interleukin-13 (IL-13) and interleukin-4 (IL-4) pathway-related genes, such as STAT1, SOCS1 and JAK, in preeclampsia has been investigated [12]. Although studies suggest the importance of expression alternations and SNPs in cytokines, each of them has its own drawbacks, and a combination of both tests is needed for diagnostic purposes. Therefore, the hypothesis of significant expression changes and mutations in the IL-13 and IL-4 pathway’s key cytokines should be studied.
There are two main methods to evaluate the expression changes in a specific pathway. The first one applies statistical models to see which genes are differentially expressed by comparing normal individuals and patients [13,14]. Then, it finds those up- or downregulated genes included in the pathway and uses them to diagnose the disorder based on the genes found. This method considers each gene separately, which causes low accuracy. However, the second method applies expression patterns of a specific pathway. This method uses gene profiles and their particular expression patterns to diagnose a disease [15]. This study applied the second method and used two deep learning algorithms to diagnose preeclampsia based on IL-4 and IL-13 pathway expression patterns. Two of the leading deep learning structures are the multilayer perceptron (MLP) and graph convolutional neural network (GCNN). This study used both of them for designing its models to select the best one with better metrics. Moreover, two additional specific SNPs in IL-13 were tested to cover the expression of deep learning model defects. Therefore, the present study aimed to study the relationship between preeclampsia risk and rs2069740 (T to A exchange) and rs34255686 (C to A exchange) polymorphisms of IL-13 while evaluating the expression patterns of IL-13 and IL-4 pathway genes in this disease.

2. Methods

2.1. Data Collection and Preprocessing

In the present study, we first searched the terms “Preeclampsia” and “Normal Pregnancy” in the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) database on 3 May 2022. The database contains a vast number of datasets related to various studies. We selected the GSE149440 microarray dataset which combined the GSE149434, GSE149436 and GSE149437 datasets. The dataset contained 735 whole blood samples and three different groups (“Normal Pregnancy”, “Early Preeclampsia” and “Preterm Birth”). The platform used was GPL28460 or Affymetrix Human Transcriptome Array 2.0, including 32,800 probes. First, raw CEL files were downloaded through the GEOquery package in R. Initial preprocessing was performed on the data, including backlight removal, data normalization based on the RMA method and data transfer to a logarithmic basis based on 2 using the affy package. Samples with the preterm birth condition were excluded from the study, and only early preeclampsia (<34 weeks because the rate of morbidities declines considerably after this gestational age in women with preeclampsia and the induction of labor is recommended after 34 weeks of gestation) and normal pregnancy samples remained. As the dataset contained multiple studies, batch effect removal was conducted using the limma package.

2.2. Deep Learning Neural Network Model Design

We applied neural networks and deep learning to classify healthy and preeclampsia blood samples. There are many types of neural networks; here, we selected MLP and CNN. To design the CNN, a dataset in the form of images was needed. To convert the format of our dataset into an image format, we applied the method used in [16]. First, we downloaded the human protein–protein interaction network from the Stanford Network Analysis Project (SNAP, https://snap.stanford.edu/) on 10 May 2022. It is a CSV file containing one column that shows protein–protein interactions organized by their Entrez ID, each one separated by a comma. For instance, the interaction between GAPDH and GRM1 is shown by 2597, 2911. Then, a graph of the interactions was constructed, each node representing a gene and each vertex representing its expression. The edges show the connections between the proteins and the graph type is an undirected graph because the impact of each protein on the other one is unknown based on the collected data. The graph structure at first was designed for all protein interactions in GSE149440. Then, the IL-13 and IL-4 signaling pathway gene list was downloaded from the GSEA (https://www.gsea-msigdb.org/) on 20 May 2022, which linked us to the Reactome database (https://reactome.org/). Afterwards, all interactions except those between the mentioned pathway genes were excluded from the constructed graph. To be able to pool graph signals, we first needed to coarsen the graph (i.e., to find out which vertices to group together). Then, we ended up having multiple graphs—not unlike a pyramid—with each at one level of resolution. The finest graph is where the input data lies. The coarsest graph is where the data at the output of the graph convolutional layers lies. Then, we computed the Laplacian graph for each of our graphs, defined by their adjacency matrices. For learning, we used a CNN graph with the following hyperparameters. Two convolutional layers were employed with 32 convolutional filters and a polynomial order of 20. Size 2 maximum pooling was applied to both convolutional layers. Two fully connected layers, on the other hand, had 512 and 128 units, respectively. The activation function of a rectified linear unit (ReLU) was used and cross-entropy loss was kept to a minimum. For MLP, four layers were constructed, with 111, 42, 21 and 10 ReLUs, respectively. In MLP, only the expression matrix of the pathway genes was considered as the input, which contained 111 genes as input features.

2.3. Experimental Design

For the case-control study, approved by the Islamic Azad University Kazerun Branch Ethics Committee (IR.IAU.KAU.REC.1398.004), conducted in 2019 and 2020, 150 preeclampsia patients and 150 normal healthy pregnant women from Zeynabieh Hospital in Shiraz, Iran, were selected. Demographic characteristics are shown in Table 1. Before entering the study groups, written informed consent was gained from all the participants. Preeclamptic women were included who presented the signs and symptoms of systole >140 mm Hg and diastole >90 mm Hg on two occasions at least 4 h apart (the mild form of preeclampsia) or a shorter interval timing of systole >160 mm Hg and diastole >110 mm Hg (the severe form of preeclampsia) after 20 weeks’ gestation with accompanying proteinuria ≥300 mg upon a 24 h urine collection; or UPCR ≥ 0.3 mg/mg; or a urine protein dipstick reading ≥2+. The control group was healthy pregnant women, without hypertension, with the same gestational age (≥20 weeks), who had been referred to the midwifery clinic of the same hospital to receive prenatal care within the same timeframe. The exclusion criteria were defined as pregnant women with a history of chronic hypertension and current antihypertensive treatment, autoimmune and any cardiac/renal disease, and liver disease/diabetic neuropathy.

2.4. DNA Extraction and Genotyping of Polymorphisms

After collecting 5 mL peripheral blood samples in EDTA tubes, genomic DNA was extracted using a Genomic DNA Isolation Kit (GeNet Bio, Daejeon, Korea), using the salting out method. To genotype rs2069740(T/A) and rs34255686(C/A) polymorphisms, the amplification refractory mutation system PCR (ARMS-PCR) method was carried out. For each polymorphism, two external primers (to check the performance of the PCR) and two allele-specific internal primers (to detect each allele) were designed (the designed primer sequences are reported in Table 2). PCR was performed in a total volume of 23.1 μL, including 1 μL of template DNA, 11 μL of 2× Master Mix RED (Ampliqon), 0.8 μL (0.39 pmol) of each primer and 7.9 μL of H2O. The cycling conditions were as follows: initial denaturation for 5 min at 94 °C, followed by 30 cycles at 94 °C for 40 s (denaturation), annealing temperature as in Table 2 for 40 s, 1 min at 72 °C (extension) and a final extension for 7 min at 72 °C. PCR products were run by standard electrophoresis on 2% agarose gel for 10 min and visualized on a UV transilluminator. The band lengths are presented in Table 2.

2.5. Software and Statistics

All data preprocessing and RMA calculations were conducted in R version 4.1.0. The deep learning model design was conducted in Python 3.10 and using the TensorFlow package. The figures were drawn in GraphPad Prism 9. On the other hand, all samples collected were analyzed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Chi-square testing was performed to evaluate the differences in the allele and genotype frequencies. P values less than 0.05 were considered statistically significant.

3. Results

3.1. 111 Genes Are Connected to the IL-13 and IL-4 Signalling Pathway

Using the GSE149440, an expression matrix was constructed based on the RMA method. As this study only needed early preeclampsia and normal blood samples, 355 out of the 735 samples were removed from the matrix. The number of samples is demonstrated in Table 3. A total of 380 samples remained, 66 of which were of early preeclampsia and 314 of the control. IL-4 and IL-13 pathway gene expression levels were extracted from the modified expression matrix. The genes linked to this pathway are shown in Supplementary Table S1. Moreover, the expression matrix contained 32 batches, so we removed their effect through the limma package and prepared a new expression matrix for designing deep learning models, as shown in Supplementary Table S2. However, because the studies used the same platform and methods for data generation, the batch effect could not affect the data considerably.

3.2. Two Deep Learning Models to Diagnose Preeclampsia through IL-13 and IL-4 Pathway Expression Data

In the present study, we designed two deep learning models for diagnostic purposes, GCNN and MLP. The GCNN model used a structure based on IL-13 and IL-4 pathway connections. This means that the model considered the biological aspects of the hypothesis. On the other hand, the MLP model only used the expression matrix as given features for model training. Therefore, we aimed to compare the accuracy of the pathway connection-based model with the usual MLP model that did not consider any biological background. The structure of each model is depicted in Figure 1A–C. Although The outcomes of both models showed high accuracy (Table 4), the MLP model classification power was better than the GCNN model. Although both models could significantly differentiate normal pregnancy from preeclampsia, there was still about a 20% error in them that needed to be resolved.

3.3. The Significant SNPs in IL-13 the Gene Might Improve the Accuracy of the Expression-Based Deep Learning Model

According to the genotype and allele frequencies of the IL-13 rs2069740(T/A) and rs34255686(C/A) polymorphisms summarized in Table 5, the frequency of alleles in both polymorphic positions (prs2069740 = 0.009; prs34255686 = 0.00) and the genotype frequencies for rs34255686(C/A) polymorphisms (p = 0.002) differed significantly between the patient and control groups. No significant difference was observed between the studied groups in the genotype frequency of rs2069740(T/A) polymorphisms (p = 0.099). Moreover, there was no significant difference in the combined genotype analyses except for the TT–AA genotypes (p = 0.001).
Further, we analyzed the association between preeclampsia risk markers such as seizures, proteinuria, edema, diabetes, multipara, hypertension, gravida, hyperthyroidism, HELLP syndrome, history of abortion, and history of preeclampsia and rs2069740(T/A) and rs34255686(C/A) polymorphisms. Except in the cases of HELLP syndrome (p = 0.008) and edema (p = 0.047) in the position of rs34255686 and multipara (p = 0.02) and gravida (p = 0.015) markers in the case of rs2069740, no significant difference was detected for other markers (Table 6).

4. Discussion

Preeclampsia is a frequent pregnancy condition that is linked to increased maternal morbidity and death, as well as intrauterine fetal development restriction [17]. As the diagnosis of this fatal disorder can be very time-consuming and inaccurate, we aimed to examine a deep learning-based expression model and introduce significant SNPs in preeclampsia for future diagnostic purposes [18].
Deep learning models in preeclampsia diagnosis have been used in some previous research. Previous studies have considered some phenotypic parameters as features for their deep learning model training for preeclampsia. For instance, M Tahir et al. applied 17 phenotypic parameters of women to detect preeclampsia based on some metabolic and physiological features [19]. Another study used long short-term memory (LSTM) neural networks to diagnose preeclampsia based on time series data [20]. Moreover, Q Wang et al. used ultrasonic image features in the diagnosis of perinatal outcomes of severe preeclampsia through a convolutional neural network model [21]. In addition, R Bennett et al. applied an imbalance-aware deep neural network to rank the most critical risk factors of preeclampsia and use them to diagnose it at its early stages [22]. Although all of the previous studies have their benefits, as clinical technologies are improving and the focus of most of them are on a high throughput and molecular data for their high accuracy and detail, we believe that models should move away from this type of data for better prediction and classification. Thus, in this study, we tried for the first time to design a model for the early diagnosis of preeclampsia based on molecular data, such as expression values and SNPs.
Many studies have referred to some genes whose expression or mutations are vital in the occurrence of preeclampsia. We first gathered those genes and found out that many of them are related to cytokines and their related pathways. Then, we selected one of the pathways that was linked to many of the referred genes in previous studies. However, almost none of them directly mentioned the IL-13 and IL-4 signaling pathway; they suggested the genes connected to this pathway as being preeclampsia risk factors, initiators or progressors [23,24,25,26,27,28,29,30,31,32]. Therefore, in the current study, we examined the role of the pathway’s genes in preeclampsia. We designed two models to assess each one’s performance. Obviously, the MLP model revealed better results with an overall accuracy of 82.11% and an average F1-score of 82.32% compared to the GCNN model with an 83.16% overall accuracy and 75.51 weighted average F1-score. However, we suggest that increasing the number of samples could improve the GCNN model results. Moreover, it is possible to consider all gene interactions in the design of the GCNN model. This study did not consider all genes because of the enormous number of features (about 32,000) present against the small number of samples. Moreover, as the connections among genes are limited in one pathway, the GCNN model could not achieve the best performance. Furthermore, as this is the first study that used expression data for deep learning model design, we added a simple SNP test for a better combined test to improve our model. We aimed for a test that could easily be applied in clinics.
Since the role of IL-13 polymorphisms as peptide cytokines belonging to the T helper 2 family and coded by the gene IL-13 in the chromosomal location of 5q31.1 in preeclampsia was not yet revealed by experimental investigation [33], this study aimed to investigate the relationship between IL-13 gene polymorphisms and preeclampsia risk. We selected two possible polymorphic sites of IL-13, including rs2069740(T/A) and rs34255686(C/A). In our study, significant differences were found in the frequency of alleles in both mentioned polymorphic positions and genotype frequencies for rs34255686(C/A) polymorphism between the patient and control groups, but on the contrary, we did not observe differences in the genotype frequencies of rs2069740(T/A) polymorphisms. Moreover, in our study, a significant difference was only observed in the TT–AA combined genotypes between the patient and control groups. So, due to these observed significant differences, rs2069740(T/A) and rs34255686(C/A) polymorphisms of IL-13 were considered relevant with an increased risk of preeclampsia. Moreover, in a similar study, Liu et al. suggested that IL-27 polymorphisms may be involved in the development of preeclampsia in the Chinese population [34]. In a study by Fan et al., the IL-10-592A/C genetic variant was observed to be associated with preeclampsia risk in pregnant women [35]. Song et al. indicated that the IL-10-592A/C (rs1800872) polymorphism was associated with an increased risk of early-onset preeclampsia in a Chinese population [11]. Raguema et al. suggested that the IL-10-819T/T variant and the ATA haplotype, which are associated with the low production of IL-10, represent genetic risk factors for preeclampsia in Tunisian women [36]. Quach et al. showed that an SNP combination (+3027C/C and +3187G/G) was significantly more prevalent in preeclampsia cases [37]. Pacheco et al. also found that 509CT/869TC combined genotypes were significantly associated with an increased risk of preeclampsia [38]. Subsequently, determining the effects of rs2069740(T/A) and rs34255686(C/A) polymorphisms on preeclampsia risk markers showed no significant difference between the two groups for other risk markers, except for HELLP syndrome and edema in the position of rs34255686 and multipara and gravida markers in the position of rs2069740 polymorphisms. PFAB, et al. also reported that carrying the C allele of the interleukin-6 polymorphisms (interleukin-6 S174G > C) was significantly associated with new-onset edema in pregnant women [39]. Wang et al. showed a significant association between the TNF-α-308G/A polymorphism and parity (Wang et al., 2018). Similarly, no significant relation in a study by Lisi et al. was found between preeclampsia risk factors, such as systolic and diastolic blood pressure, proteinuria and endothelin-1 type-A receptor gene polymorphism (7231 G4A) [40]. Although the current report revealed the genetic association between rs2069740(T/A) and rs34255686(C/A) polymorphisms in the IL-13 gene and the risk of preeclampsia, a more significant sample size is required to validate the observations of the present study.

5. Conclusions

IL-4 and IL-13 pathways can considerably affect preeclampsia and deep learning models based on these pathway genes predicting patients’ status with high accuracy. We also concluded that polymorphisms of IL-13 in the positions of rs2069740(T/A) and rs34255686(C/A) contribute to the risk of preeclampsia. We believe that this combined test of two single nucleotide polymorphisms and an expression-based deep learning model is able to predict preeclampsia in very early pregnancy. It is worth noting that this model and SNP-based testing could be invaluable in screening high-risk pregnancies in clinical practice and could serve as a decision-making reference for clinicians.
Therefore, we suggest more investigation of a diagnostic model based on both expression and polymorphism results. Finally, to better understand the pathology of the disease due to its life-threatening properties and likely involvement of more polymorphic sites in its pathogenesis, research into more polymorphisms and the expression patterns of IL-4 and IL-13 pathway genes is needed.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/biomedicines11051257/s1.

Author Contributions

Conceptualization, S.N. and M.M.; methodology, S.N. and M.M.; formal analysis, S.N., M.M., A.S., S.P. and K.K.V.; investigation, S.N., M.M., A.S., S.P. and K.K.V.; resources, S.N., M.M., A.S., S.P. and K.K.V.; data curation, S.N., M.M., A.S., S.P. and K.K.V.; writing—original draft preparation, S.N. and K.K.V.; writing—review and editing, S.N., M.M. and K.K.V.; visualization, S.N.; supervision, S.N. and M.M.; funding acquisition, S.N. and M.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee Review Board of the Islamic Azad University’s Kazerun Branch.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

We thank Hadiseh Jalali (Isfahan University of Art) for the figure illustrations and Amirhossein Hajialiasgary Najafabadi (University of Isfahan) for the consultation on the experimental design and deep learning models used in this study.

Conflicts of Interest

No potential competing interests are reported by the authors.

Abbreviations

SNPSingle nucleotide polymorphism
ILInterleukin
MLPMultilayer perceptron
GCNNGraph convolutional neural network
GEOGene Expression Omnibus
SNAPStanford Network Analysis Project
ARMS-PCRAmplification refractory mutation system PCR

References

  1. Karrar, S.A.; Hong, P.L.; Preeclampsia. StatPearls Publishing. 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK570611/ (accessed on 9 September 2022).
  2. Erez, O.; Romero, R.; Jung, E.; Chaemsaithong, P.; Bosco, M.; Suksai, M.; Gallo, D.M.; Gotsch, F. Preeclampsia and eclampsia: The conceptual evolution of a syndrome. Am. J. Obstet. Gynecol. 2022, 226, 786–803. [Google Scholar] [CrossRef] [PubMed]
  3. Nirupama, R.; Divyashree, S.; Janhavi, P.; Muthukumar, S.P.; Ravindra, P.V. Preeclampsia: Pathophysiology and management. J. Gynecol. Obstet. Hum. Reprod. 2021, 50, 101975. [Google Scholar] [CrossRef]
  4. Caplan, M.; Keenan-Devlin, L.S.; Freedman, A.; Grobman, W.; Wadhwa, P.D.; Buss, C.; Miller, G.E.; Borders, A.E.B. Lifetime Psychosocial Stress Exposure Associated with Hypertensive Disorders of Pregnancy. Am. J. Perinatol. 2021, 38, 1412–1419. [Google Scholar] [CrossRef]
  5. Rana, S.; Lemoine, E.; Granger, J.P.; Karumanchi, S.A. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ. Res. 2019, 124, 1094–1112. [Google Scholar] [CrossRef]
  6. Black, K.D.; Horowitz, J.A. Inflammatory Markers and Preeclampsia: A Systematic Review. Nurs. Res. 2018, 67, 242–251. [Google Scholar] [CrossRef] [PubMed]
  7. Ives, C.W.; Sinkey, R.; Rajapreyar, I.; Tita, A.T.N.; Oparil, S. Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 76, 1690–1702. [Google Scholar] [CrossRef]
  8. Aggarwal, R.; Jain, A.K.; Mittal, P.; Kohli, M.; Jawanjal, P.; Rath, G. Association of pro- and anti-inflammatory cytokines in preeclampsia. J. Clin. Lab. Anal. 2019, 33, e22834. [Google Scholar] [CrossRef]
  9. Chen, H.; Zhang, Y.; Dai, L.; Song, Y.; Wang, Y.; Zhou, B.; Zhou, R. Association between polymorphisms in CXCR2 gene and preeclampsia. Mol. Genet. Genom. Med. 2019, 7, e00578. [Google Scholar] [CrossRef]
  10. Abedin, D.A.; Esmaeilzadeh, E.; Amin-Beidokhti, M.; Pirjani, R.; Gholami, M.; Mirfakhraie, R. ACE gene rs4343 polymorphism elevates the risk of preeclampsia in pregnant women. J. Hum. Hypertens. 2018, 32, 825–830. [Google Scholar] [CrossRef] [PubMed]
  11. Song, L.; Zhong, M. Association between Interleukin-10 gene polymorphisms and risk of early-onset preeclampsia. Int. J. Clin. Exp. Pathol. 2015, 8, 11659–11664. [Google Scholar]
  12. Liu, H.; Wang, W.; Liu, C. Increased expression of IFN-γ in preeclampsia impairs human trophoblast invasion via a SOCS1/JAK/STAT1 feedback loop. Exp. Ther. Med. 2021, 21, 112. [Google Scholar] [CrossRef]
  13. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [Google Scholar] [CrossRef]
  14. Smyth, G.K. Limma: Linear Models for Microarray Data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor; Springer: New York, NY, USA, 2005; pp. 397–420. [Google Scholar]
  15. Slonim, D.K. From patterns to pathways: Gene expression data analysis comes of age. Nat. Genet. 2002, 32, 502–508. [Google Scholar] [CrossRef]
  16. Chereda, H.; Bleckmann, A.; Kramer, F.; Leha, A.; Beissbarth, T. Utilizing Molecular Network Information via Graph Convolutional Neural Networks to Predict Metastatic Event in Breast Cancer. Stud. Health Technol. Inform. 2019, 267, 181–186. [Google Scholar]
  17. Eiland, E.; Nzerue, C.; Faulkner, M. Preeclampsia 2012. J. Pregnancy 2012, 2012, 586578. [Google Scholar] [CrossRef] [PubMed]
  18. Wiles, K.; Chappell, L.C.; Lightstone, L.; Bramham, K. Updates in Diagnosis and Management of Preeclampsia in Women with CKD. Clin. J. Am. Soc. Nephrol. 2020, 15, 1371–1380. [Google Scholar] [CrossRef] [PubMed]
  19. Tahir, M.; Badriyah, T.; Syarif, I. Classification Algorithms of Maternal Risk Detection For Preeclampsia With Hypertension During Pregnancy Using Particle Swarm Optimization. EMITTER Int. J. Eng. Technol. 2018, 6, 236–253. [Google Scholar] [CrossRef]
  20. Sakinah, N.; Tahir, M.; Badriyah, T.; Syarif, I. LSTM with adam optimization-powered high accuracy preeclampsia classification. In Proceedings of the 2019 International Electronics Symposium (IES), Surabaya, Indonesia, 27–28 September 2019; pp. 314–319. [Google Scholar]
  21. Wang, Q.; Liu, D.; Liu, G. Value of Ultrasonic Image Features in Diagnosis of Perinatal Outcomes of Severe Preeclampsia on account of Deep Learning Algorithm. Comput. Math. Methods Med. 2022, 2022, 4010339. [Google Scholar] [CrossRef] [PubMed]
  22. Bennett, R.; Mulla, Z.D.; Parikh, P.; Hauspurg, A.; Razzaghi, T. An imbalance-aware deep neural network for early prediction of preeclampsia. PLoS ONE 2022, 17, e0266042. [Google Scholar] [CrossRef]
  23. Jonsson, Y.; Rubèr, M.; Matthiesen, L.; Berg, G.; Nieminen, K.; Sharma, S.; Ernerudh, J.; Ekerfelt, C. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J. Reprod. Immunol. 2006, 70, 83–91. [Google Scholar] [CrossRef]
  24. Salazar Garcia, M.D.; Mobley, Y.; Henson, J.; Davies, M.; Skariah, A.; Dambaeva, S.; Gilman-Sachs, A.; Beaman, K.; Lampley, C.; Kwak-Kim, J. Early pregnancy immune biomarkers in peripheral blood may predict preeclampsia. J. Reprod. Immunol. 2018, 125, 25–31. [Google Scholar] [CrossRef] [PubMed]
  25. Vishnyakova, P.A.; Volodina, M.A.; Tarasova, N.V.; Marey, M.V.; Tsvirkun, D.V.; Vavina, O.V.; Khodzhaeva, Z.S.; Kan, N.E.; Menon, R.; Vysokikh, M.Y.; et al. Mitochondrial role in adaptive response to stress conditions in preeclampsia. Sci. Rep. 2016, 6, 32410. [Google Scholar] [CrossRef]
  26. Choi, S.J.; Oh, S.Y.; Kim, J.H.; Sadovsky, Y.; Roh, C.R. Increased expression of N-myc downstream-regulated gene 1 (NDRG1) in placentas from pregnancies complicated by intrauterine growth restriction or preeclampsia. Am. J. Obstet. Gynecol. 2007, 196, e1–e7. [Google Scholar] [CrossRef]
  27. Nuzzo, A.M.; Giuffrida, D.; Zenerino, C.; Piazzese, A.; Olearo, E.; Todros, T.; Rolfo, A. JunB/cyclin-D1 imbalance in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise. Placenta 2014, 35, 483–490. [Google Scholar] [CrossRef] [PubMed]
  28. Li, G.; Wang, Y.; Cao, G.; Ma, Y.; Li, Y.X.; Zhao, Y.; Shao, X.; Wang, Y.L. Hypoxic stress disrupts HGF/Met signaling in human trophoblasts: Implications for the pathogenesis of preeclampsia. J. Biomed. Sci. 2022, 29, 8. [Google Scholar] [CrossRef] [PubMed]
  29. Gumusoglu, S.; Scroggins, S.; Vignato, J.; Santillan, D.; Santillan, M. The Serotonin-Immune Axis in Preeclampsia. Curr. Hypertens. Rep. 2021, 23, 37. [Google Scholar] [CrossRef]
  30. Cecati, M.; Giannubilo, S.R.; Saccucci, F.; Sartini, D.; Ciavattini, A.; Emanuelli, M.; Tranquilli, A.L. Potential Role of Placental Klotho in the Pathogenesis of Preeclampsia. Cell Biochem. Biophys. 2016, 74, 49–57. [Google Scholar] [CrossRef]
  31. Espino, Y. Sosa.S.; Flores-Pliego, A.; Espejel-Nuñez, A.; Medina-Bastidas, D.; Vadillo-Ortega, F.; Zaga-Clavellina, V.; Estrada-Gutierrez, G. New Insights into the Role of Matrix Metalloproteinases in Preeclampsia. Int. J. Mol. Sci. 2017, 18, 1448. [Google Scholar]
  32. Qu, H.; Yu, Q.; Jia, B.; Zhou, W.; Zhang, Y.; Mu, L. HIF-3α affects preeclampsia development by regulating EVT growth via activation of the Flt-1/JAK/STAT signaling pathway in hypoxia. Mol. Med. Rep. 2021, 23, 68. [Google Scholar] [CrossRef]
  33. Mannon, P.; Reinisch, W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012, 61, 1765–1773. [Google Scholar] [CrossRef]
  34. Liu, B.; Li, Y.; Yao, Y.; Li, H.; Liang, H.; Xin, M.; Wang, L.; Zhao, L.; Lin, J.; Liu, S. Polymorphisms of the IL27 gene in a Chinese Han population complicated with pre-eclampsia. Sci. Rep. 2016, 6, 23029. [Google Scholar] [CrossRef] [PubMed]
  35. Fan, D.M.; Wang, Y.; Liu, X.L.; Zhang, A.; Xu, Q. Polymorphisms in interleukin-6 and interleukin-10 may be associated with risk of preeclampsia. Genet. Mol. Res. 2017, 16, gmr16018588. [Google Scholar] [CrossRef] [PubMed]
  36. Raguema, N.; Gannoun, M.B.A.; Zitouni, H.; Meddeb, S.; Benletaifa, D.; Lavoie, J.L.; Almawi, W.Y.; Mahjoub, T. Interleukin-10 rs1800871 (-819C/T) and ATA haplotype are associated with preeclampsia in a Tunisian population. Gestation. Hypertens. 2018, 11, 105–110. [Google Scholar] [CrossRef] [PubMed]
  37. Quach, K.; Grover, S.A.; Kenigsberg, S.; Librach, C.L. A combination of single nucleotide polymorphisms in the 3′untranslated region of HLA-G is associated with preeclampsia. Hum. Immunol. 2014, 75, 1163–1170. [Google Scholar] [CrossRef]
  38. Salas-Pacheco, J.; Vazquez-Alaniz, F.; Martínez, S.; Quiñones, A.M.; Aguilar-Durán, M. Combined genotypes-509CT/869TC of the TGFB1 gene associated with preeclampsia. Rev. Int. De Contam. Ambient. 2014, 30, 45–51. [Google Scholar]
  39. Pfab, T.; Chen, Y.P.; Slowinski, T.; Richter, C.M.; Godes, M.; Arck, P.C.; Halle, H.; Hocher, B. Impact of genes related to immune tolerance and inflammation (tumour necrosis factor-alpha, interleukin-6) on blood pressure, protein excretion and oedema in pregnancy. J. Hypertens. 2005, 23, 2187–2191. [Google Scholar] [CrossRef]
  40. Lisi, V.; Paternoster, D.M.; Stecca, A.; Micciché, F.; Fantinato, S.; Leon, A.; Damante, G.; Fabbro, D.; Clementi, M. Investigation of endothelin-1 type A receptor gene polymorphism (−231 G > A) in preeclampsia susceptibility. J. Matern. Fetal Neonatal Med. 2007, 20, 145–149. [Google Scholar] [CrossRef]
Figure 1. Prediction of preeclampsia from systemic inflammation through deep learning methods. (A) The main dysfunctions and disorders related to preeclampsia. As shown, SDEV release in the blood through placental dysfunction might affect endothelial cells, immune cells and the coagulation process, which might lead to preeclampsia disorder. In this study, only one of the pathways related to systemic inflammation was studied. (B) Graph of the convolutional neural network (GCNN) summary. Microarray expression data were taken from patients, and normal samples were used to build the IL-4 and IL-13 pathway graph. Then, convolutional and pooling layers were applied for classification. (C) The structure of the multilayer perceptron (MLP) model. The model contains three hidden layers with ReLUs as the activation functions for all of them. The input layer also contains 111 units representing all 111 genes linked to the mentioned pathway.
Figure 1. Prediction of preeclampsia from systemic inflammation through deep learning methods. (A) The main dysfunctions and disorders related to preeclampsia. As shown, SDEV release in the blood through placental dysfunction might affect endothelial cells, immune cells and the coagulation process, which might lead to preeclampsia disorder. In this study, only one of the pathways related to systemic inflammation was studied. (B) Graph of the convolutional neural network (GCNN) summary. Microarray expression data were taken from patients, and normal samples were used to build the IL-4 and IL-13 pathway graph. Then, convolutional and pooling layers were applied for classification. (C) The structure of the multilayer perceptron (MLP) model. The model contains three hidden layers with ReLUs as the activation functions for all of them. The input layer also contains 111 units representing all 111 genes linked to the mentioned pathway.
Biomedicines 11 01257 g001
Table 1. Demographic characteristics of participants in the two groups.
Table 1. Demographic characteristics of participants in the two groups.
VariablePreeclampsiaControlp-Value
N = (150)N = (150)
Age, years30.09 ± 6.8727.23 ± 4.860.239
Range16–4816–38
BMI, kg/m226.19 ± 3.6025.83 ± 3.470.214
Gestational age, median (range), wk
(at the time of sampling)
32 (28–33)32 (28–33)
Mode of delivery
(at the time of sampling)
Emergency caesarean section
Pre-labour caesarean section
7 (4.67)
3 (2)
Systolic blood pressure, mmHg151.84 ± 10.78109.37 ± 11.07<0.001
Diastolic blood pressure, mmHg94.95 ± 6.8864.85 ± 9.02<0.001
Table 2. Designed primer sequences for the ARMS-PCR reactions, annealing temperature and amplicon lengths.
Table 2. Designed primer sequences for the ARMS-PCR reactions, annealing temperature and amplicon lengths.
SNPPrimer SequenceAnnealing
Temperature (°C)
Fragment Length
rs2069740(T/A)FO:CCTCTGCACAGTTTGGAC
RO:TCTGTCCAGCAATCCAGG
FI:AATGCCGTGGCCTCTGCT
RI:CAGCCTTAGTCCAGGTCAGAGA
58.2 °CT:151 bp
A:384 bp
rs34255686(C/A)FO: CCTCTGCACAGTTTGGAC
RO: TCTGTCCAGCAATCCAGG
FI: CCTTCTCAATAAGTCCAT
RI: CTGGTTCTGGGTGATGTTT
56.8 °CC:186 bp
A:220 bp
Table 3. The grouping information of patients of the GSE140449.
Table 3. The grouping information of patients of the GSE140449.
GroupSubgroupTotal Number
ControlTNL(176)314
TL(138)
Early PreeclampsiaNone66
Preterm BirthNone355
Table 4. Model Evaluation.
Table 4. Model Evaluation.
ModelAccuracyF1-Score (Weighted)
Graph Convolutional Neural Network (GCNN)83.16%75.51%
Multalayer Perceptron (MLP)82.11%82.32%
Table 5. Genotype and allele frequencies and combined genotypes of the IL-13 (rs2069740(T/A) and rs34255686(C/A)) polymorphisms in preeclamptic and normal pregnant women.
Table 5. Genotype and allele frequencies and combined genotypes of the IL-13 (rs2069740(T/A) and rs34255686(C/A)) polymorphisms in preeclamptic and normal pregnant women.
Genotype and AlleleControl GroupPatient Groupp-Value
n (%)n (%)
rs2069740(T/A)
AA20(13.3)9(6)0.099
TT123(82)133(88.7)
AT7(4.7)8(5.3)
A47(15.7)26(8.7)0.009
T253(84.3)274(91.3)
rs34255686(C/A)
CC121(80.7)141(94)0.002
AA15(10)3(2)
CA14(9.3)6(4)
A12(4)44(14.7)0.00
C288(96)256(85.3)
Genotype combination (rs2069740–rs34255686)
AA–CC18(12)9(6)0.06
AA–AA2(1.3)0(0)0.1
TT–CC117(78)106(70.7)0.14
TT–AA0(0)13(8.7)0.001
TT–CA6(4)14(9.3)0.06
AT–CC6(4)7(4.7)0.7
AT–AA1(7)1(7)1
Table 6. Associations between the IL-13 (rs2069740(T/A) and rs34255686(C/A)) polymorphisms and preeclampsia risk markers in preeclamptic and healthy pregnant women.
Table 6. Associations between the IL-13 (rs2069740(T/A) and rs34255686(C/A)) polymorphisms and preeclampsia risk markers in preeclamptic and healthy pregnant women.
rs2069740
(T/A)
Genotype
n (%)
p-Valuers34255686
(C/A)
Genotype
n (%)
p-Value
AATTAT CCAACA
Seizures
Present
0
(0)
1
(100)
0
(0)
0.9Seizures
Present
1
(100)
0
(0)
0
(0)
0.88
Absent9
(6)
132
(88)
8
(5.4)
Absent120
(80.5)
15
(10)
14
(9.4)
Proteinuria
Absent
3
(5.7)
47
(88.7)
3
(5.7)
0.9Proteinuria
Absent
43
(81)
4
(7)
6
(11)
0.5
Trace1
(5.6)
16
(88)
1
(5.6)
Trace16
(88.9)
0
(0)
2
(11)
13
(6.5)
41
(89.3)
2
(4.3)
135
(76)
7
(15)
4
(8.7)
22
(13)
12
(80)
1
(6.7)
211
(73)
3
(20)
1
(6.7)
30
(0)
13
(92)
1
(7.1)
313
(93.1)
0
(0)
1
(6.7)
40
(0)
4
(100)
0
(0)
43
(75)
1
(25)
0
(0)
Edema
Absent
0
(0)
23
(100)
0
(0)
0.131Edema
Absent
15
(65)
4
(17)
4
(17)
0.047
18
(8.8)
78
(85)
5
(5.5)
179
(86)
4
(4.4)
8
(8.8)
20
(0)
24
(96)
1
(4)
218
(72)
6
(24)
1
(4)
31
(9.1)
8
(72.7)
2
(18.2)
39
(81)
1
(9.1)
1
(9.1)
Diabetes
Present
1
(11)
8
(88)
0
(0)
0.629Diabetes
Present
7
(77.8)
2
(22.2)
0
(0)
0.311
Absent8
(5.7)
125
(88)
8
(5.7)
Absent114
(80.7)
13
(9.2)
14
(9.9)
Multipara
Primary
11
(8)
115
(83)
12
(8.7)
0.02Multipara
Primary
122
(88.4)
10
(7.2)
6
(4.3)
0.252
Multiple18
(11.1)
141
(87)
3
(1.9)
Multiple140
(86.6)
8
(4.9)
14
(8.6)
Hypertension
Mild
8
(6.9)
101
(87.7)
7
(6.4)
0.7Hypertension
Mild
93
(80)
10
(8.6)
13
(11)
0.38
Moderate1
(0)
24
(33.3)
1
(17.1)
Moderate22
(84.6)
3
(11)
1
(3.8)
Severe0
(0)
8
(100)
0
(0)
Severe6
(75)
2
(25)
0
(0)
Gravida Present 2
(33.3)
4
(66.7)
0
(0)
0.015Gravida Present 5
(83.3)
1
(16.7)
0
(0)
0.64
Absent7
(4.9)
129
(89.6)
8
(5.6)
Absent116
(80.6)
14
(9.7)
14
(9.7)
Hyperthyroidism
Present
0
(0)
16
(94)
1
(5.9)
0.54Hyperthyroidism
Present
14
(82.4)
2
(11.8)
1
(5.9)
0.85
Absent9
(6.8)
117
(80)
7
(5.3)
Absent107
(80.1)
13
(9.8)
13
(9.8)
HELLP syndrome
Present
0
(0)
1
(100)
0
(0)
0.9HELLP syndrome
Present
0
(0)
0
(0)
1
(100)
0.008
Absent9
(6)
132
(88.6)
8
(5.4)
Absent121
(81.2)
15
(10)
13
(8.7)
History of abortion
Present
1
(3.3)
26
(86)
3
(10)
0.36History of abortion
Present
26
(86.7)
4
(13.3)
0
(0)
0.13
Absent8
(6.7)
107
(89.2)
5
(4.2)
Absent95
(79.3)
11
(9.2)
14
(11.7)
History of preeclampsia
Present
1
(7.7)
10
(76.9)
2
(15)
0.225History of preeclampsia
Present
11
(84)
1
(7.7)
1
(7.7)
0.9
Absent8
(5.8)
123
(89)
6
(4.4)
Absent110
(80.5)
14
(10)
13
(9.5)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Saadaty, A.; Parhoudeh, S.; Khashei Varnamkhasti, K.; Moghanibashi, M.; Naeimi, S. Preeclampsia Susceptibility Assessment Based on Deep Learning Modeling and Single Nucleotide Polymorphism Analysis. Biomedicines 2023, 11, 1257. https://doi.org/10.3390/biomedicines11051257

AMA Style

Saadaty A, Parhoudeh S, Khashei Varnamkhasti K, Moghanibashi M, Naeimi S. Preeclampsia Susceptibility Assessment Based on Deep Learning Modeling and Single Nucleotide Polymorphism Analysis. Biomedicines. 2023; 11(5):1257. https://doi.org/10.3390/biomedicines11051257

Chicago/Turabian Style

Saadaty, Aida, Sara Parhoudeh, Khalil Khashei Varnamkhasti, Mehdi Moghanibashi, and Sirous Naeimi. 2023. "Preeclampsia Susceptibility Assessment Based on Deep Learning Modeling and Single Nucleotide Polymorphism Analysis" Biomedicines 11, no. 5: 1257. https://doi.org/10.3390/biomedicines11051257

APA Style

Saadaty, A., Parhoudeh, S., Khashei Varnamkhasti, K., Moghanibashi, M., & Naeimi, S. (2023). Preeclampsia Susceptibility Assessment Based on Deep Learning Modeling and Single Nucleotide Polymorphism Analysis. Biomedicines, 11(5), 1257. https://doi.org/10.3390/biomedicines11051257

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop